Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Regulus Therapeutics Q3 EPS $(0.50) Misses $(0.49) Estimate

Regulus Therapeutics (NASDAQ:RGLS) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.49) by 2.04 percent. This is a 50 percent increase over losses of $(1.00) per share
byBenzinga Newsdesk
November 10, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Regulus Therapeutics (NASDAQ:RGLS) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.49) by 2.04 percent. This is a 50 percent increase over losses of $(1.00) per share from the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts